title: [Systemic lupus erythematosus presenting as Stevens-Johnson syndrome].
abstract: Stevens-Johnson syndrome and toxic epidermal necrolysis are life-threatening dermatological conditions. Their most common cause is medication. However, in a small proportion of patients these dermatological conditions could be the first presentation of systemic lupus erythematosus. We now describe a 34-year-old patient who presented with manifestations of Stevens-Johnson as a first feature of systemic lupus erythematosus. Systemic lupus erythematosus reveled by Stevens-Johnson syndrome has been infrequently reviewed in the previous literature. This diagnosis should be considered when cutaneous adverse drug reactions occur without clear drug causality.
authors.affiliation: Service de médecine interne, hôpital des forces de sécurité intérieure, rue Tahar Ben Achour, 2070 La Marsa, Tunisie. Electronic address: syrinebellakhal@yahoo.fr.
authors.forename: S
authors.initials: S
authors.lastname: Bellakhal
authors.affiliation: Service de médecine interne, hôpital des forces de sécurité intérieure, rue Tahar Ben Achour, 2070 La Marsa, Tunisie.
authors.forename: B
authors.initials: B
authors.lastname: Ben Kaab
authors.affiliation: Service de médecine interne, hôpital des forces de sécurité intérieure, rue Tahar Ben Achour, 2070 La Marsa, Tunisie.
authors.forename: Z
authors.initials: Z
authors.lastname: Teyeb
authors.affiliation: Service de médecine interne, hôpital des forces de sécurité intérieure, rue Tahar Ben Achour, 2070 La Marsa, Tunisie.
authors.forename: A
authors.initials: A
authors.lastname: Souissi
authors.affiliation: Service de médecine interne, hôpital des forces de sécurité intérieure, rue Tahar Ben Achour, 2070 La Marsa, Tunisie.
authors.forename: F
authors.initials: F
authors.lastname: Derbel
authors.affiliation: Service de médecine interne, hôpital des forces de sécurité intérieure, rue Tahar Ben Achour, 2070 La Marsa, Tunisie.
authors.forename: M-H
authors.initials: MH
authors.lastname: Douggui
mesh_terms: D000328:Adult; D000740:Anemia / Q000209:etiology; D018771:Arthralgia / Q000209:etiology; D001323:Autoantibodies / Q000097:blood; D003176:Complement C3 / Q000032:analysis; D003422:Critical Care; D005148:Facial Dermatoses / Q000209:etiology; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000032:analysis; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D008775:Methylprednisolone / Q000627:therapeutic use; D052016:Mucositis / Q000209:etiology; D011241:Prednisone / Q000627:therapeutic use; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy / Q000209:etiology*
chemical_list: D001323:Autoantibodies; D003176:Complement C3; D007074:Immunoglobulin G; D006886:Hydroxychloroquine; D011241:Prednisone; D008775:Methylprednisolone
keywords: Lupus erythematosus; Lupus érythémateux systémique; Nécrolyse épidermique toxique; Stevens-Johnson syndrome; Syndrome de Stevens-Johnson; Toxic epidermal necrolysis